Lopinavir

Evidence Level: L4

Predicted Indications: 3

Lopinavir

Pharmacist Assessment Report

Lopinavir: From HIV Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Lopinavir was originally used to treat HIV infection and AIDS. The TxGNN model predicts it may be effective for simian immunodeficiency virus (SIV) infection, but the support so far consists only of 3 preclinical publications in macaques and no registered clinical trials.

Quick Overview

Item	Content
Original Indication	HIV infectious disease; AIDS
Predicted New Indication	Simian immunodeficiency virus infection
TxGNN Prediction Score	0.9990
Evidence Level	L4
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, lopinavir is an HIV-1 protease inhibitor, and its efficacy in HIV infection is established. SIV is a closely related lentivirus with a structurally similar protease, so antiviral activity is biologically plausible.

The literature found is preclinical, from macaque studies. These include quadruple antiretroviral therapy with rapid viral decay, a chimeric virus (SHIV) carrying an HIV-1 protease gene for testing protease inhibitors, and oral HAART that included lopinavir/ritonavir. This is essentially an extension of the original antiviral indication to an animal model, not a new human therapeutic indication. The high score (0.9990) mainly reflects similarity to the approved HIV indication rather than independent evidence.

Two other predictions were also reviewed. Feline acquired immunodeficiency syndrome (score 0.9990) is a veterinary indication with no trials and no literature. A rare neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter (score 0.9990) has no evident mechanistic link; its score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
16973590	2006	Preclinical animal study	Journal of Virology	Four SIV-infected cynomolgus macaques given a 7-day course of quadruple antiretroviral therapy showed rapid viral decay
17350308	2007	Preclinical animal study	Microbes and Infection	A novel SHIV carrying the HIV-1 protease gene was built as an in vivo tool for testing protease inhibitors in rhesus macaques
12951220	2003	Preclinical animal study	Journal of Virological Methods	Oral AZT, 3TC and lopinavir/ritonavir for 28 days in two SHIV-infected macaques, assessing the effect on the CD8 subset

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02285533	KALETRA	Not listed	Not listed
02312301	KALETRA	Not listed	Not listed
02243644	KALETRA	Not listed	Not listed

Safety Considerations

Contraindication-related conditions (from the knowledge graph, not label text): The knowledge graph links lopinavir to caution or contraindication in the following groups:

Cardiac: long QT syndrome (including familial), torsades de pointes, sudden cardiac arrest, heart conduction disease, atrioventricular block, cardiomyopathy (including hypertrophic), myocardial ischemia, coronary artery disease
Liver and biliary: liver disease, cirrhosis, gallbladder disease, chronic hepatitis B and C, hyperbilirubinemia, Gilbert syndrome
Metabolic: diabetes mellitus, diabetic ketoacidosis, hyperglycemia, hypertriglyceridemia, familial combined hyperlipidemia, potassium deficiency
Other: pancreatitis, hemophilia

Drug Interactions: 65 interactions are recorded. Examples:

Major: dolasetron, papaverine
Moderate: acarbose, dapagliflozin, famotidine, levofloxacin, metformin, ondansetron, palonosetron, and several laxatives (bisacodyl, castor oil, lactulose, magnesium citrate, among others)
Minor: cimetidine, clotrimazole

Lopinavir is typically co-formulated with ritonavir, a CYP3A4 inhibitor, which adds to interaction and feasibility concerns. Please refer to the package insert for label warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The only support is preclinical macaque data, and SIV infection is an animal-model extension of the original HIV indication rather than a new human indication. The high TxGNN score reflects similarity to the existing indication, not independent efficacy evidence.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Mechanism of action data (for example, from DrugBank)
Approved indication text for the three Canadian DINs
A defined human or clinically relevant use case, since SIV and feline AIDS are animal indications
Review of cardiac, hepatic and metabolic risks and the interaction profile
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.